Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment

Round 1

Reviewer 1 Report

The presentation of the review of the literature by the authors is an excellent analysis of Alzheimer's disease in terms of changes in specific biomarkers and clinical manifestations.

The perspective of using animal models to identify new therapies in Alzheimer’s disease is also approached comparatively. The studies included in this article are very well selected and are current.

The authors provide an overview of the effectiveness of therapy for different stages of the disease and also discuss new therapeutic perspectives.

A real problem that is discussed extensively in the manuscript is that transgenic mouse models do not show all the manifestations identified in people with Alzheimer's disease. Due to this aspect the value of the article is remarkable. The manuscript presents the current limitations underlying the development of therapies in Alzheimer's disease. At the same time, the paper presents the perspective of developing new early diagnostic strategies and new therapies with high efficiency in the case of using small APP-KI mice as a model.

The results presented by the authors provide very important and useful new benchmarks for developing new therapies with high-efficiency for Alzheimer’s disease.

The way the manuscript was written, the structure and the presentation of the observations from the specialized literature are of a high quality. That is why I recommend publishing the review in its current form.

Reviewer 2 Report

Dear Authors,

thank you for a great article. The manuscript presents several AD mouse models from the aspect of biomarkers and cognitive impairment. Moreover, it discusses their potential as tools to provide novel AD therapeutic approaches.  The paper is written very well, it is comprehensive and detailed. I have no objections and recommend this article to be published.